- Healthcare Roundup: Research, Policy & Legal - Aug 16Today's Healthcare wrap covers emerging therapies, digital-care research and a broad federal review of Epic Systems. Read what happened, how markets were positioned as of Aug 14, and what you should watch next.
- Healthcare Roundup: FDA, Legal Battles - Aug 16A landmark FDA approval for a myeloma drug sits alongside legal and policy headaches for health tech and medical billing. Scientific advances and obesity redefinitions add nuance as markets head into the long weekend.
- Healthcare Wrap-Up Aug 15Bristol Myers scored an FDA win while legal and regulatory pressures weigh on health tech and insurers. Research advances offer long-term upside; near-term risks keep sentiment balanced.
- Healthcare Sector Update - Aug 15Biotech wins and public health alarms headline a varied Healthcare landscape heading into the long weekend. FDA approvals and legal probes sit alongside global Ebola concerns and vaccine debates.
- Healthcare Moves: BMY Approval, Policy Hits - Aug 14Bristol Myers won FDA approval for a new myeloma drug while vaccine, legal and billing code stories kept the sector's outlook mixed. Read what moved stocks and what you should watch next.
- Healthcare: Innovation Meets Policy Headwinds - Aug 14Early-morning reports highlight new biotech advances from malaria research to lung cancer data, plus policy risks for Medicaid and gender-affirming care. Read what could move stocks and care today.
- Healthcare: Cancer Data, Policy Shifts - Aug 13Today brought encouraging cancer science and clinical trial updates alongside policy and access shocks that could reshape payers, providers and drugmakers. Read what moved the sector, what to watch next, and how you might set your scan for tomorrow.
- Healthcare Faces Policy and Safety Risks - Aug 13Policy scrutiny and safety signals lead today’s healthcare headlines. CMS work-rule criticism, a near 400% rise in liver-injury calls, and Medicare AI payment incentives create fresh regulatory and operational risks.
- Healthcare: Policy Headwinds, Biotech Wins - Aug 12Today’s healthcare headlines mixed scientific progress and commercial defenses with major policy shifts from the administration. You’ll want to track regulatory moves, late-stage clinical wins, and how policy headlines could reshape access and reimbursement.
- Healthcare Morning Brief - Aug 12Safety questions around a newly approved rare disease drug and rising patient prepayment rules are top headlines. You should track regulatory moves, Medicaid policy and screening trends today.
- Healthcare Evening Wrap-Up, Aug 11R&D advances and fresh biotech leadership competed with policy headwinds and consumer safety alarms in today’s healthcare headlines. Read a concise wrap of what moved the sector and what you should watch next.
- Healthcare: Approvals, AI Pushback, Policy Risks - Aug 11A new Alzheimer’s immune-cell map and an accelerated FDA approval brighten the healthcare landscape, but policy friction around AI, harm reduction, and GLP-1 access keeps risks front and center. Read what you should watch today.
- Healthcare Wrap - Aug 10: Trials, FDA News, M&AClinical and regulatory setbacks tempered gains from dealmaking and genetic breakthroughs today. Read how FDA actions, a CF trial failure, and M&A will shape sector moves into tomorrow.
- Healthcare: Breakthroughs and Headwinds - Aug 10A potential one-time regimen to clear HIV in newborns headlines today alongside AI integration and rising regulatory scrutiny. This briefing lays out what could move stocks and policy on Aug 10.
- Healthcare Roundup - Aug 9Research on a low-fat vegan diet, infection risks after firearm injuries, changes to breast screening in Australia, and public-health coverage dominated the weekend. Read our take on implications for healthcare and related companies heading into Monday.
- Healthcare Roundup: Policy, Safety, R&D - Aug 9A mixed set of healthcare headlines heads into the long weekend, from a complete brown rat genome aiding disease research to HHS moves on organ procurement and insurers seeking a 14% premium hike. Read key takeaways and what you should watch next.
- Healthcare Sector Roundup - Aug 8Mixed healthcare headlines head into the long weekend, from promising drug demand and a glioblastoma target to HHS decertification, insurer rate filings and wildfire health risks. Read what matters for your exposure.
- Healthcare Snapshot: Safety, Policy, Drug News - Aug 8A mixed set of healthcare headlines heads into the long weekend, from drug demand and safety fixes to policy moves that could reshape research and organ donation. Read what you need to know and what to watch heading into Monday.
- Healthcare Sector Wrap - Aug 7Today brought encouraging R&D and commercial activity, from AI-backed bionic-eye work to a major pain-drug IPO, but policy moves and organ procurement problems temper the outlook. Read what you need to know for Monday.
- Healthcare Gains on Approvals, M&A - Aug 7Regulatory wins and a major acquisition lead the healthcare morning. FDA approval for a melanoma therapy, Tarsus' up-to-$800M Alkeus buy, and new AML biology are driving sector momentum today.
- Healthcare Wrap Aug 6Approvals for Replimune and Takeda, a sizable Alkeus exit, and leadership and policy moves made headlines. You should watch Medicare pricing timelines and upcoming trial readouts.
- Healthcare Briefing: Moderna, Outbreaks - Aug 6Moderna won FDA approval for the first mRNA flu vaccine while biotech IPOs keep momentum. At the same time, Ebola spread, a cyclospora outbreak and a hospital cyberattack raise fresh risks.
- Healthcare Wrap: Earnings, Safety & CDC News - Aug 5A mixed day for healthcare: strong IPO and obesity‑drug headlines sat alongside trial safety concerns, a Medicare fraud settlement and new dementia research. Read what this means for your watchlist tomorrow.
- Healthcare: Research, Policy, Earnings - Aug 5Research breakthroughs around PTSD and Candida sit alongside policy and political risks that could reshape drug pricing and guidance. Pfizer cost cuts and Vertex competition add industry-level implications you’ll want to track today.
- Healthcare Mixed Signals - Aug 4Today's healthcare news was a mixed bag, from new Alzheimer’s blood tests and AI governance wins to rising overdose deaths, an Ebola surge, and biotech program cancellations. Read what moved the sector and what to watch next.
- Healthcare Headlines: Medicaid, Outbreaks, M&A - Aug 4Policy shifts and public-health stories set the tone in healthcare today, with Medicaid enrollment tech, a cyclospora outbreak, research gaps, and M&A rumors moving markets. Read what you should watch for and how these items could affect health stocks and sector risk.
- Healthcare Mixed Signals - Aug 3 WrapMedicare's move on breakthrough device payments and merger rumors sent shocks through stocks, while science and therapy advances kept innovation momentum alive. Read how these mixed signals matter for your healthcare exposure.
- Healthcare Mixed Signals on Aug 3Policy shifts and coverage losses are colliding with efficiency tools and clinical advances in healthcare. Today’s briefing breaks down what matters for insurers, hospitals, and health-tech investors.
- Healthcare Pricing Probe and Research - Aug 2A Michigan Supreme Court ruling greenlights a probe into $LLY insulin pricing, putting pricing and regulatory risk back in focus heading into the Aug 3 session. Meanwhile, several new studies add scientific context for infectious disease and neuroscience research.
- Healthcare Faces Policy, Trial Headwinds - Aug 2Clinical setbacks and renewed policy fights set a cautious tone for healthcare heading into Monday. Investors should watch trial readouts, 340B regulation developments, and the DR Congo Ebola response.
- Healthcare Faces Setbacks and Policy Battles - Aug 1Clinical and policy headlines capped the week as a late July clinical failure and renewed 340B rebate plans put pressure on pharma and hospitals heading into Aug 3. Research advances and corporate moves offer pockets of balance.
- Healthcare Roundup: Trials, Policy & Research - Aug 1A mixed morning for healthcare: a key cardiovascular trial setback and renewed 340B rebate proposals grab headlines, while new research on MASLD, breastfeeding, and industry moves add nuance. Heading into the long weekend, here’s what you need to know.
- Healthcare Mixed Signals - Jul 30 WrapJ&J’s near $2.6B option for in vivo CAR-T and Teladoc’s revenue cut drove headlines, while FTC action and policy moves added regulatory noise. Read which catalysts you should track next.
- Healthcare: FDA Reviews, Policy Risks in Focus - Jul 30FDA advisory panels, policy shifts and scientific advances are shaping Healthcare pre-market action. Read what moved the sector overnight and what you should watch today.
- Healthcare Wrap-Up: Deals, Policy and Risks - Jul 29Biotech partnerships and a fresh wave of reverse-merger deals energized markets today, while regulatory and payer headwinds kept gains in check. Read what moved the sector and what to watch next.
- Healthcare Morning Briefing Jul 29Regulatory scrutiny and industry wins collide today as Capricor faces an FDA advisory panel while Centene posts a surprise profit and guidance lift. You’ll want to watch FDA action, policy risk, and AI safety headlines.
- Healthcare Sector Roundup - Jul 28Centene's big profit and a $118M biotech raise stood out amid industry-wide policy and regulatory noise. You’ll want to track FDA AI guidance, GSK's $2.5B cuts, and visa policy fallout.
- Healthcare Mixed Signals - Jul 28Biotech and health tech showed fresh momentum overnight, from safer Alzheimer’s signals to a race to cure AATD, while public health funding cuts, an outbreak and loan caps raise headwinds. Read what you should watch today.
- Healthcare Mixed Signals - Jul 27Regulatory moves, public health surges and digital-health progress set a mixed tone for healthcare on Jul 27. Read what matter to you today and the catalysts to watch.
- Healthcare Wrap Jul 26: AI, Memory, Military TestsToday's healthcare headlines include AI-driven surgical analysis, new cognitive research on distraction, and a Pentagon plan to screen testosterone. Read how these developments could touch diagnostics, medtech and health costs as markets head into the long weekend.
- Healthcare Hits Headwinds - Jul 26Safety, pipeline setbacks and public-health strains dominated Sunday headlines for healthcare. From a gene-editing death probe to Sanofi shelving an eczema drug, the sector faces near-term risk and regulatory scrutiny.
- Healthcare Sector Wrap Jul 25Scientific advances and consumer-health innovation competed with pipeline setbacks, regulatory controversy and public-health strains. Heading into the long weekend, the sector shows mixed signals for investors.
- Healthcare Sector Roundup - Jul 25A mixed morning for healthcare: rising infectious disease cases and company setbacks sit alongside promising screening research and active regulatory headlines. Here’s what you need to know heading into the long weekend.
- Healthcare Mixed Signals - Jul 24Today’s Healthcare wrap covers rising measles cases, a Sanofi pipeline pullback, mixed FDA peptide guidance, and fresh research on cancer drugs and placebo biology. Read how these developments could shape policy, payer dynamics, and R&D headlines into next week.
- Healthcare Morning Briefing - Jul 24Science and policy are tugging healthcare in different directions today. New lab findings and a gene-editing IPO sit alongside a measles comeback and shifting federal research priorities.
- Healthcare Mix: Breakthroughs and Headwinds - Jul 23Clinical breakthroughs and new drug filings pushed scientific momentum today, while supply shortfalls, a parasite outbreak and payer pressures created offsets. Read what moved the sector and what to watch next.
- Healthcare Movers: GSK Approval, FDA Peptide Panel - Jul 23GSK wins a speedy FDA OK after a $10.6B deal, Arrowhead posts encouraging data, and an FDA advisory panel scrutinizes wellness peptides. Policy moves and tech advances add context.
- Healthcare Mixed Signals, Jul 22 WrapClinical wins in rare-disease and lipid therapy clashed with policy and global-health headwinds today. Read what moved stocks, which catalysts matter next, and how you might think about risk.
- Healthcare Roundup, Jul 22Europe approves a retinal implant as policy, funding and drug setbacks create a mixed bag for healthcare. Read what matters for markets and what you should watch today.
- Healthcare Sector Faces Headwinds - Jul 21Policy actions and R&D disappointments set the tone for healthcare on Jul 21, with a $1B Medicaid pause, a high-profile clinical failure and funding shifts for HIV groups. Read on for what to watch tomorrow.